

Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study

INTRODUCTION

Frontotemporal dementia (FTD) is a heterogeneous group of neurodegenerative diseases with an onset usually before the age of 65 years even if it can appear also in older ages.¹

On cognitive tests, patients with FTD show deficits in executive functions, social cognition and language, whereas the initial performances in memory and visuo-construction tasks usually are preserved.¹ The general approach to detect cognitive decline in dementia is to repeat cognitive testing and observe changes over time. However, exposure to similar tasks could improve performance as the individual gets familiar with both the tasks themselves and the test setting (ie, practice effect or learning effect).^{2,3}

Different attempts to adjust for practice effects in repeated testing have been proposed.⁴ However, recent research suggests that the phenomenon of practice effects can provide useful information. Patients with neurological and psychiatric conditions show lower practice effects than healthy controls, and individuals with mild cognitive impairment (MCI) that do not show practice effects are more likely to develop Alzheimer disease (AD) within a year than individuals with MCI that have preserved practice effects.³ In addition to the findings of lower practice effects in patients with dementia, Hassenstab *et al*⁵ found that preclinical individuals who later progressed to AD had substantially reduced practice effects in episodic memory compared with cognitively stable individuals. Thus, absence of practice effects might serve as an early marker for cognitive decline.

To our knowledge, practice effects have never been investigated in FTD before. The aim of this study was to examine practice effects in the GENetic Frontotemporal dementia Initiative (GENFI) cohort. More specifically, we investigated whether there is a difference in practice effects between presymptomatic mutation carriers (PMC) and mutation non-carriers (NC).

MATERIALS AND METHODS

Participants

All participants (317 NC, 327 PMC and 159 affected mutation carriers (AMC))

were recruited through GENFI from January 2012 to March 2018 (online supplemental table 1). Of the 803 participants, 471 had two visits; 249 had three visits; and 108 had four visits. After the fourth visit, the number of participants rapidly decreased and only 12 had six test occasions (online supplemental figure 1).

Statistics

A global cognitive score was calculated including the mean z-scores of all tests in the standardised GENFI neuropsychological battery. Additionally, practice effects for different cognitive domains were explored. A linear mixed-effects model was applied to examine potential practice effects. Further details including neuropsychological tests, composite score calculation and model selection criteria are described in the online supplemental materials.

RESULTS

Practice effects

An increase in mean global cognitive test scores was seen in NC over the first five visits (online supplemental figure 2). When investigating different cognitive domains, practice effects were found across visits 1–3 in all domains except for visuo-construction (online supplemental table 2). The largest practice effect was observed in memory and social cognition. After the third visit, there was a plateau, and the practice effects between visits 3 and 4 as well as visits 4 and 5 were not statistically

significant. In contrast, a progressive decline in the mean global score was identified longitudinally in AMC, as could be expected (online supplemental figure 2). PMC carrying a *C9orf72* expansion and with less than 5 years to expected symptom onset (PMC-C9 in proximity to onset) showed no practice effect on their global test score and had the same mean performance at all three visits (figure 1A and online supplemental table 3). Furthermore, PMC-C9 with more than 5 years to expected onset had a lower practice effect between visits 1 and 2 than NC; however, the total practice effect (visits 1–3) was not significantly different from NC.

Similar to PMC-C9, there was a lower practice effect across visits 1–3 in PMC with a progranulin (*GRN*) mutation in proximity to onset compared with NC. However, PMC-GRN in proximity to onset appear to initially have a practice effect but subsequently do not improve their performance at the third visit (figure 1B).

PMC with a *MAPT* mutation (PMC-MAPT) had a similar trajectory in mean cognitive test score across visits 1–3 as NC (figure 1C).

DISCUSSION

In this study, we explored practice effects due to repeated cognitive assessments in a large cohort of individuals with genetic presymptomatic or symptomatic FTD as well as non-mutation carrier family members. Practice effects have been








Figure 1 Trajectories of global cognitive test scores in NC and PMC by mutated gene. (A) PMC-C9 and NC (grey line, NC; yellow solid line, PMC-C9 with >5 years to expected symptom onset; yellow dashed line, PMC-C9 with <5 years to expected symptom onset). (B) PMC-GRN and NC (grey line, NC; blue solid line, PMC-GRN with >5 years to expected symptom onset; blue dashed line, PMC-GRN with <5 years to expected symptom onset). (C) PMC-MAPT and NC (grey line, NC; pink solid line, PMC-MAPT with >5 years to expected symptom onset; pink dashed line, PMC-MAPT with <5 years to expected symptom onset). All lines are fitted from the same linear mixed-effect model but plotted in A–C to simplify visualisation. Error bars represent the SEs of the means. §The difference between PMC-MAPT with >5 years to expected symptom onset and NC is no longer observed when PMC-MAPTs are compared with age-matched and family-matched controls. C9, chromosome 9 open reading frame 72; GRN, progranulin; MAPT, microtubule-associated protein tau; NC, non-carrier; PMC, presymptomatic mutation carrier.

suggested to provide useful information of the progression of cognitive decline but have never been studied in the context of FTD before. Compared with their baseline test scores, NC improved in global cognition at each visit (visits 2 and 3). Presymptomatic individuals carrying the *C9orf72* expansion or a *GRN* mutation had significantly lower practice effects than NC, and this difference was most apparent in PMC-C9 within 5 years of expected symptom onset. However, it is not possible to know if the stable performance over time in PMC in proximity to onset is due to lower practice effects per se or an actual cognitive decline that is masked by practice effects. The question of genuine practice effects applies also to AMC, who showed a progressive decline in global cognitive test scores at each visit. The scores measured after repeated testing in AMC might include a 'hidden' practice effect, and therefore the true cognitive dysfunction would in fact be greater than what was captured in the test scores. Cognitive functions in FTD are expected to decline over the test interval used in this study (mean 1.3 years). Consequently, a potential absence of practice effects in clinical FTD, as reported in AD,³ cannot be evaluated with the current setup but could be addressed if the retest is performed within days or weeks of the first assessment. Besides the PMC in proximity to onset, also PMC-C9 with more than 5 years to expected symptom onset had lower practice effects than NC which could not be explained by early conversion into a symptomatic stage. Progression of brain atrophy in *C9orf72* expansion carriers can be slow, and some patients have been described with a remarkably long disease duration.¹ Pathological changes in the brain of *C9orf72* expansion carriers are present already in early adulthood, and the potential neurodevelopmental effects could lead to a long prodromal phase in PMC-C9. Previous findings show that cognitive performance in PMC is not different from NC until very close to the disease onset,¹ which is in line with the results of the current study. Nevertheless, an inability to use acquired skills from previous tests might be a marker for very early disease development in PMC-C9. However, the diagnostic potential of practice effects and whether they can be used for differentiating PMC-C9 from NC are yet to be explored.

As the field of FTD research is greatly evolving and treatment opportunities are emerging, knowledge about different stages of the disease is highly required. As we are preparing for clinical trials, several

initiatives have been searching for both fluid biomarkers as surrogate endpoints as well as clinical and neuropsychological tests used to evaluate a future treatment response. Practice effects can have implications for the interpretation of longitudinal changes in cognitive performance as it could impact estimations of treatment effects after an intervention, particularly early in the disease course. Furthermore, one could speculate that identifying individuals with lower-than-expected practice effects would be a cost-effective approach for inclusion into clinical trials.³ The presence of practice effects should thus be considered in future clinical trials especially if neuropsychological measures are included as end points.

Linn Öijerstedt ^{1,2}, Christin Andersson,^{3,4} Vesna Jelic,¹ John Cornelis van Swieten ⁵, Lize C Jiskoot ⁵, Harro Seelaar ⁵, Barbara Borroni ⁶, Raquel Sanchez-Valle,⁷ Fermin Moreno,^{8,9} Robert Laforce Jr,¹⁰ Matthis Synofzik,^{11,12} Daniela Galimberti ^{13,14}, James Benedict Rowe ¹⁵, Mario Masellis,¹⁶ Maria Carmela Tartaglia,¹⁷ Elizabeth Finger ¹⁸, Rik Vandenbergh, ^{19,20} Alexandre de Mendonca,²¹ Fabrizio Tagliavini,²² Isabel Santana,^{23,24} Simon Ducharme ^{25,26}, Christopher R Butler,^{27,28} Alexander Gerhard ^{29,30}, Johannes Levin,^{31,32} Adrian Danek ³¹, Markus Otto ³³, Giovanni Frisoni,³⁴ Roberta Ghidoni,³⁵ Sandro Sorbi ^{36,37}, Jonathan Daniel Rohrer ³⁸, Caroline Graff,^{1,2} Genetic Frontotemporal Dementia Initiative (GENFI)

¹Department of Neurobiology, Care Sciences and Society, Neurogeriatrics, Karolinska Institute, Stockholm, Sweden

²Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Stockholm, Sweden

³Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

⁴Department of Medical Psychology, Karolinska University Hospital, Stockholm, Sweden

⁵Neurology, Erasmus MC, Rotterdam, Netherlands

⁶Centre for Ageing Brain and Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

⁷Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic de Barcelona, Barcelona, Spain

⁸Cognitive Disorders Unit, Department of Neurology, Donostia, Donostia San Sebastian, Spain

⁹Neuroscience Area, Biodonostia Health Research Institute, Donostia San Sebastian, Spain

¹⁰Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, Faculté de Médecine, CHU de Québec-Université Laval, Montreal, Quebec, Canada

¹¹Department of Neurodegenerative Diseases, University of Tübingen, Eberhard Karls University Tübingen Hertie Institute for Clinical Brain Research, Tübingen, Germany

¹²German Centre for Neurodegenerative Diseases, Tübingen, Germany

¹³Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milano, Italy

¹⁴Centro Dino Ferrari, University of Milan, Milano, Italy

¹⁵Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

¹⁶Sunnybrook Research Institute, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

¹⁷Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada

¹⁸Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada

¹⁹Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium

²⁰Neurology Service, KU Leuven University Hospitals Leuven, Leuven, Belgium

²¹Faculty of Medicine, University of Lisbon, Lisboa, Portugal

²²Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milano, Italy

²³Neurology Service, Faculty of Medicine, Hospital and University Centre of Coimbra, Coimbra, Portugal

²⁴Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

²⁵Department of Psychiatry, McGill University Health Centre, Montreal, Quebec, Canada

²⁶McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada

²⁷Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK

²⁸Brain Sciences, Imperial College London, London, UK

²⁹Division of Neuroscience and Experimental Psychology, The University of Manchester, Manchester, UK

³⁰Geriatric Medicine and Nuclear Medicine, University of Duisburg-Essen, Duisburg, Germany

³¹Neurologische Klinik, Ludwig Maximilians University Munich, Munchen, Germany

³²German Centre for Neurodegenerative Diseases, Munchen, Germany

³³Neurology, University of Ulm, Ulm, Germany

³⁴IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

³⁵Molecular Markers Lab, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

³⁶Neurofarba, University of Florence, Firenze, Italy

³⁷IRCCS Firenze, Fondazione Don Carlo Gnocchi Onlus, Firenze, Italy

³⁸Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK

Correspondence to Dr Linn Öijerstedt, Department of Neurobiology, Care Sciences and Society, Neurogeriatrics, Karolinska Institute, Stockholm, Sweden; linn.oijerstedt@ki.se

Correction notice This article has been corrected since it was first published online. The 'Results' heading has been added in the text.

Twitter Harro Seelaar @HarroSeelaar and Simon Ducharme @sducharme66

Acknowledgements We thank all the participants and their families for contributing to the study, and also the Genetic Frontotemporal Dementia Initiative research coordinators, especially Catharina Roman and Nathalie Asperén, at the Stockholm site, who helped with arranging the visits.

Collaborators Genetic Frontotemporal Dementia Initiative (GENFI): Sónia Afonso (Instituto Ciências Nucleares Aplicadas a Saude, Universidade de Coimbra, Coimbra, Portugal), Maria Rosario Almeida (Faculty of Medicine, University of Coimbra, Coimbra, Portugal), Sarah Anderl-Straub (Department of Neurology, University of Ulm, Ulm, Germany), Anna Antonell (Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Barcelona, Spain), Silvana Archetti (Biotechnology Laboratory, Department of Diagnostics, ASST Brescia Hospital,

Brescia, Italy), Andrea Arighi (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Centro Dino Ferrari, Milan, Italy), Mircea Balasa (Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain), Myriam Barandiaran (Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain; Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain), Nuria Bargalló (Imaging Diagnostic Center, Hospital Clínic, Barcelona, Spain), Robert Bartha (Department of Medical Biophysics, The University of Western Ontario, London, Ontario, Canada; Centre for Functional and Metabolic Mapping, Roberts Research Institute, The University of Western Ontario, London, Ontario, Canada), Benjamin Bender (Department of Diagnostic and Interventional Neuroradiology, University of Tübingen, Tübingen, Germany), Alberto Benussi (Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Italy), Luisa Benussi (Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy), Valentina Bessi (Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy), Giuliano Binetti (Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy), Sandra Black (Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada), Martina Bocchetta (Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK), Sergi Borrego-Ecija (Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain), Jose Bras (Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, Michigan, MI 49503, USA), Rose Bruffaerts (Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium), Marta Cañada (CITA Alzheimer, San Sebastian, Gipuzkoa, Spain), Valentina Cantoni (Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy), Paola Caroppo (Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy), David Cash (Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK), Miguel Castelo-Branco (Faculty of Medicine, University of Coimbra, Coimbra, Portugal), Rhian Convery (Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK), Thomas Cope (Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK), Giuseppe Di Fede (Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy), Alina Diez (Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain), Diana Duro Faculty of Medicine, University of Coimbra, Coimbra, Portugal), Chiara Fenoglio (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Centro Dino Ferrari, Milan, Italy), Camilla Ferrari (Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy), Catarina B. Ferreira (Laboratory of Neurosciences, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal), Nick Fox (Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK), Morris Freedman (Baycrest Health Sciences, Rotman Research Institute, University of Toronto, Toronto, Canada), Giorgio Fumagalli (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,

Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Centro Dino Ferrari, Milan, Italy), Alazne Gabilondo (Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain), Roberto Gasparotti (Neuroradiology Unit, University of Brescia, Brescia, Italy), Serge Gauthier (Alzheimer Disease Research Unit, McGill Centre for Studies in Aging, Department of Neurology & Neurosurgery, McGill University, Montreal, Québec, Canada), Stefano Gazzina (Neurology, ASST Brescia Hospital, Brescia, Italy), Giorgio Giaccone (Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy), Ana Gorostidi (Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain), Caroline Greaves (Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK), Rita Guerreiro (Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, Michigan, MI 49503, USA), Carolin Heller (Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK), Tobias Hoegen (Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany), Begoña Indakoetxea (Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain; Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain), Hans-Otto Karnath (Division of Neuropsychology, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany), Ron Keren (The University Health Network, Toronto Rehabilitation Institute, Toronto, Canada), Tobias Langheinrich (Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK, Manchester Centre for Clinical Neurosciences, Department of Neurology, Salford Royal NHS Foundation Trust, Manchester, UK), Maria João Leitão (Centre of Neurosciences and Cell Biology, Universidade de Coimbra, Coimbra, Portugal), Albert Lladó (Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain), Gemma Lombardi (Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy), Sandra Loosli (Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany), Carolina Maruta (Laboratory of Language Research, Centro de Estudos Egas Moniz, Faculty of Medicine, University of Lisbon, Lisbon, Portugal), Simon Mead (MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK), Lieke Meeter (Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands), Gabriel Miltenberger (Faculty of Medicine, University of Lisbon, Lisbon, Portugal), Rick van Minkelen (Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, Netherlands), Sara Mitchell (Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada), Katrina Moore (Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK), Benedetta Nacmias (Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy), Jennifer Nicholas (Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK), Jaume Olives (Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain), Sebastian Ourselin (School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK), Alessandro Padovani (Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Italy), Jessica Panman (Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands), Janne M. Pappa (Department of Neurology, Erasmus Medical Center, Rotterdam,

Netherlands), Georgia Peakman (Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK), Michela Pievani (Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy), Yolande Pijnenburg (Amsterdam University Medical Centre, Amsterdam VUmc, Amsterdam, Netherlands), Cristina Polito (Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", Nuclear Medicine Unit, University of Florence, Florence, Italy), Enrico Premi (Stroke Unit, ASST Brescia Hospital, Brescia, Italy), Sara Prioni (Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy), Catharina Prix (Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany), Rosa Rademakers (Department of Neurosciences, Mayo Clinic, Jacksonville, Florida, USA), Veronica Redaelli (Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy), Tim Rittman (Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK), Ekaterina Rogava (Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada), Pedro Rosa-Neto (Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, McGill University, Montreal, Québec, Canada), Giacomina Rossi (Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy), Martin Rosser (Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK), Beatriz Santiago (Neurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal), Elio Scarpini (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurodegenerative Diseases Unit, Milan, Italy; University of Milan, Centro Dino Ferrari, Milan, Italy), Sonja Schönecker (Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany), Elisa Semler (Department of Neurology, University of Ulm, Ulm), Rachele Shafei (Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK), Christen Shoesmith (Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada), Miguel Tábuas-Pereira (Neurology Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal), Mikel Tainta (Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain), Ricardo Taipa (Neuropathology Unit and Department of Neurology, Centro Hospitalar do Porto - Hospital de Santo António, Oporto, Portugal), David Tang-Wai (The University Health Network, Krembil Research Institute, Toronto, Canada), David L Thomas (Neuroimaging Analysis Centre, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, Queen Square, London, UK), Paul Thompson (Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK), Håkan Thonberg (Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden), Carolyn Timberlake (Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK), Pietro Tiraboschi (Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy), Emily Todd (Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK), Philip Van Damme (Neurology Service, University Hospitals Leuven, Belgium; Laboratory for Neurobiology, VIB-KU Leuven Centre for Brain Research, Leuven, Belgium), Mathieu Vandenbulcke (Geriatric Psychiatry Service, University Hospitals Leuven, Belgium; Neuropsychiatry, Department of Neurosciences, KU Leuven, Leuven, Belgium), Michele Veldsman (Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK), Ana Verdelho (Department of Neurosciences and Mental Health, Centro Hospitalar Lisboa Norte - Hospital de Santa

Maria & Faculty of Medicine, University of Lisbon, Lisbon, Portugal), Jorge Villanua (OSATEK, University of Donostia, San Sebastian, Gipuzkoa, Spain), Jason Warren (Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK), Carlo Wilke Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany; Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany), Ione Woollacott (Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK), Elisabeth Wlasich (Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany), Henrik Zetterberg (Dementia Research Institute, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK), Miren Zulaica (Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain).

Contributors LÖ contributed to study coordination and acquisition, analysis, visualisation and interpretation of the data, as well as drafting and revision of the manuscript. CA and CG contributed to the study design, acquisition and interpretation of the data, and revision of the manuscript. JDR contributed to the study design, acquisition of data and revision of the manuscript. VJ, JCVS, LCJ, HS, BB, RS-V, FM, RL, MS, DG, JBR, MM, MCT, EF, RV, AdM, FT, IS, SD, CRB, AG, JL, AD, MO, GBF, RG and SS contributed to the acquisition of data and study coordination, and critically reviewed and revised the manuscript.

Funding This work was supported by grants from SRC/VR 529-2014-7504, VR 2015-02926, VR 2018-02754, VR 2019-02248; JPND GENFI-PROX, the Swedish FTD Initiative-Schörling Foundation, Swedish Alzheimer Foundation, Swedish Brain Foundation, Demensfonden, Stohnes foundation, Gamla Tjänarinnor, Karolinska Institutet Doctoral funding and ALF-Region Stockholm. This work was also supported by the MRC UK GENFI grant (MR/M023664/1), the Bluefield Project, the JPND GENFI-PROX grant (2019-02248), the Dioraphte Foundation (grant numbers 09-02-00); the Association for Frontotemporal Dementias Research Grant 2009; The Netherlands Organization for Scientific Research (grant HCMI 056-13-018); ZonMw Memorabel (Deltaplan Dementie, project numbers 733 050 103 and 733 050 813); and JPND PreFrontAls consortium (project number 733051042). JDR was supported by an MRC Clinician Scientist Fellowship (MR/M008525/1) and received funding from the NIHR Rare Disease Translational Research Collaboration

(BRC149/NS/MH). Several authors of this publication are members of the European Reference Network for Rare Neurological Diseases (Project ID No 739510).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Local ethics committees at each site approved the study, and all participants provided written informed consent at enrolment.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.



OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jnnp-2021-327005>).



To cite Öijerstedt L, Andersson C, Jelic V, *et al.* *J Neurol Neurosurg Psychiatry* Epub ahead of print: [please include Day Month Year]. doi:10.1136/jnnp-2021-327005

Received 1 May 2021
Accepted 25 July 2021

J Neurol Neurosurg Psychiatry 2021;**0**:1–4.
doi:10.1136/jnnp-2021-327005

ORCID iDs

Linn Öijerstedt <http://orcid.org/0000-0003-0635-6377>
John Cornelis van Swieten <http://orcid.org/0000-0001-6278-6844>
Lize C Jiskoot <http://orcid.org/0000-0002-1120-1858>
Harro Seelaar <http://orcid.org/0000-0003-1989-7527>
Barbara Borroni <http://orcid.org/0000-0001-9340-9814>
Daniela Galimberti <http://orcid.org/0000-0002-9284-5953>
James Benedict Rowe <http://orcid.org/0000-0001-7216-8679>
Elizabeth Finger <http://orcid.org/0000-0003-4461-7427>
Simon Ducharme <http://orcid.org/0000-0002-7309-1113>
Alexander Gerhard <http://orcid.org/0000-0002-8071-6062>
Adrian Danek <http://orcid.org/0000-0001-8857-5383>
Markus Otto <http://orcid.org/0000-0002-6647-5944>
Sandro Sorbi <http://orcid.org/0000-0002-0380-6670>
Jonathan Daniel Rohrer <http://orcid.org/0000-0002-6155-8417>

REFERENCES

- Ghetti B, Buratti E, Boeve B. *Frontotemporal dementias*. 1st ed. Springer International Publishing, 2021: 320.
- Calamia M, Markon K, Tranel D. Scoring higher the second time around: meta-analyses of practice effects in neuropsychological assessment. *Clin Neuropsychol* 2012;26:543–70.
- Jutten RJ, Grandoit E, Foldi NS, *et al.* Lower practice effects as a marker of cognitive performance and dementia risk: a literature review. *Alzheimers Dement* 2020;12:e12055.
- Duff K. Current topics in science and practice evidence-based indicators of neuropsychological change in the individual patient: relevant concepts and methods. *Arch Clin Neuropsychol* 2012.
- Hassenstab J, Ruvolo D, Jasielec M, *et al.* Absence of practice effects in preclinical Alzheimer's disease. *Neuropsychology* 2015;29:940–8.

SUPPLEMENTARY MATERIALS

Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study

Linn Öijerstedt^{1,2,3}, Christin Andersson^{4,5}, Vesna Jelic⁶, John C. van Swieten⁷, Lize C. Jiskoot⁷, Harro Seelaar⁷, Barbara Borroni⁸, Raquel Sanchez-Valle⁹, Fermin Moreno^{10,11}, Robert Laforce¹², Matthias Synofzik^{13,14}, Daniela Galimberti^{15,16}, James B. Rowe¹⁷, Mario Masellis¹⁸, Maria Carmela Tartaglia¹⁹, Elizabeth Finger²⁰, Rik Vandenberghe^{21,22,23}, Alexandre de Mendonça²⁴, Fabrizio Tagliavini²⁵, Isabel Santana^{26,27}, Simon Ducharme^{28,29}, Chris R. Butler^{30,31}, Alexander Gerhard^{32,33}, Johannes Levin^{34,35,36}, Adrian Danek³⁷, Markus Otto³⁸, Giovanni B Frisoni³⁹, Roberta Ghidoni⁴⁰, Sandro Sorbi^{41,42}, Jonathan D. Rohrer⁴³, Caroline Graff^{1,2,3}, on behalf of the Genetic Frontotemporal Dementia Initiative (GENFI)

AFFILIATIONS

¹Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden

²Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden

³Swedish FTD Initiative

⁴Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

⁵Department of Medical Psychology, Karolinska University Hospital, Stockholm, Sweden

⁶Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden

⁷Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands

⁸Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

⁹Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain

¹⁰Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain

¹¹Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain

¹²Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, QC, Canada

¹³Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany

¹⁴Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany

¹⁵Fondazione IRCCS Ospedale Policlinico, Milan, Italy

¹⁶University of Milan, Centro Dino Ferrari, Milan, Italy

¹⁷Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

¹⁸Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada

¹⁹Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada

²⁰Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario Canada

²¹Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium

²²Neurology Service, University Hospitals Leuven, Belgium

²³Leuven Brain Institute, KU Leuven, Leuven, Belgium

²⁴ Faculty of Medicine, University of Lisbon, Lisbon, Portugal

SUPPLEMENTARY MATERIALS

²⁵Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy

²⁶University Hospital of Coimbra (HUC), Neurology Service, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

²⁷Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

²⁸Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Québec, Canada

²⁹McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Québec, Canada

³⁰Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK

³¹Department of Brain Sciences, Imperial College London, UK

³²Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK

³³Departments of Geriatric Medicine and Nuclear Medicine, University of Duisburg- Essen, Germany

³⁴Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany

³⁵German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

³⁶Munich Cluster of Systems Neurology (SyNergy), Munich, Germany

³⁷Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany

³⁸Department of Neurology, University of Ulm, Ulm, Germany

³⁹Istituto di Recovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

⁴⁰Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

⁴¹Department of Neurofarba, University of Florence, Italy

⁴²IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy

⁴³Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK

1 Supplemental materials

1.1 Participants

The following clinical information was available for each subject: age at testing, date of testing, sex, mutation status (presymptomatic mutation carrier, PMC; affected mutation carrier, AMC; non-carrier, NC) and years of education. In addition, information on mutated gene (chromosome 9 open reading frame 72, *C9orf72*; progranulin, *GRN*; microtubule associated protein tau, *MAPT* or TANK-binding kinase 1, *TBK1*) was available for mutation carriers, and diagnosis as well as age at onset for affected mutation carriers (AMC).

The mean age at onset for mutation carriers has in a recent publication by Moore *et al.*, 2019(1) been estimated to be 58.2 years for *C9orf72*, 61.3 years for *GRN* and 49.5 years for *MAPT*. Years to expected onset was calculated based on the age of the participant minus the mean age at

SUPPLEMENTARY MATERIALS

onset for the specific mutated gene segregating in the family. For example, a 45 years old *C9orf72* mutation carrier was estimated to be 13.2 years from expected symptom onset ($45 - 58.2 = -13.2$).

1.2 Neuropsychological tests

359 participants were assessed using GENFI 1 protocol (2012-2015) and 444 participants using GENFI 2 protocol (2015-2018)(2). The following tasks were included in both GENFI 1 and GENFI 2 (i.e. all 803 participants performed the tasks): Block design(3), Boston naming test (BNT)(4), Digit symbol(3), Digit span (forward and backward)(3), Trail making test A (TMT A) and B (TMT B)(5) and Verbal fluency test (animals, letters F, A and S)(6). In GENFI 2 (n=444), the following additional tests were administered: Benson figure copy, recall and recognition(7), modified Camel and cactus test (CC)(8), Stroop colour and word test (ink and word naming, interference)(9,10), Free and cued selective reminding test (FCRST)(11), Ekman faces and Faux pas recognition test as part of the mini-SEA(12). All neuropsychological raw scores were converted into z-scores. z-scores were calculated based on mutation negative control data (individual test score minus the mean of non-carriers, divided by the standard deviation of non-carriers) and were corrected for language in language specific tasks (i.e. BNT and Verbal fluency).

1.3 Composite scores

Composite scores were calculated from reflecting different cognitive domains: language, executive function, attention and processing speed, memory, social cognition and visuoconstruction. The composite scores were calculated as the mean of the z-scores of the individual tests included in the composite (13). We treat the composite value as an estimate of a standardised score, meaning that a value of 1 is approximately 1 standard deviation (SD). The composite score of language included BNT, CC and Verbal fluency animals; executive function included TMT B, Verbal fluency letters, Digit span backward and Stroop interference; attention and processing speed included TMT A, Digit symbol, Digit span forward and Stroop ink and word naming; memory included Digit span (forward and backward) and FCRST; social cognition included Ekman faces and Faux pas recognition test (mini-SEA); and visuoconstruction included Block design and Benson figure. If there were missing data from a specific task (if a participant did not complete the whole test battery), the domain composite score was calculated based on the remaining test scores for that domain, i.e. the sum of the z-scores divided by the number of completed tests. As a sensitivity analysis, we excluded the individuals with less

SUPPLEMENTARY MATERIALS

than two thirds of completed tests (n=5) and re-ran the mixed effect model of global cognitive score. The results were the same and did not change the conclusion.

1.4 Statistical analysis

All statistical analyses and visual illustrations were performed using R version 4.0.3. P-values below 0.05 were considered statistically significant and baseline p-values were adjusted for multiple comparisons using Bonferroni corrections (number of comparisons = 63). Assumptions were assessed visually by residual plots (independence and equal variance) and normal probability plots (normality).

When assessing mean differences in numeric variables between NC, PMC and AMC, One-way ANOVA with Bonferroni post hoc tests was used (age, years of education). Chi-square tests were used for assessing sex distribution in NC, PMC and AMC.

Model selection(14) was based upon clinical relevance and Bayesian information criterion (BIC), where lower BIC was preferred. A stepwise backward selection was performed for the fixed effects using R package lmerTest v2.0-36. Mutation group (AMC, PMC or NC) or mutated gene (*C9orf72*, *GRN*, *MAPT*, NC), visit, years from baseline visit, age, age², education, sex and baseline score were included as fixed effects (independent variables) in the final models. In addition, the interaction between gene and visit was included to investigate whether the trajectories for neuropsychological test scores were different over time depending on which gene was mutated. Site and individual were included as random effects to account for within-subject correlations.

SUPPLEMENTARY MATERIALS

Supplementary Table 1. Demographic data. NC, non-carriers; PMC, presymptomatic mutation carriers; AMC, affected mutation carriers; C9orf72, chromosome 9 open reading frame 72; GRN, progranulin; MAPT, microtubule associated protein tau; TBK1, TANK-binding kinase 1; SD, standard deviation.


	Mutation group				Test statistic	
	NC	PMC	AMC	Total	p value	
N	317	327	159	803		
Age (Years)					< 0.001 ^a	AMC > PMC = NC
Mean (SD)	46.2 (14.0)	44.4 (12.0)	62.6 (8.0)	48.7 (14.0)		
Range	19.4 - 85.7	20.1 - 75.5	37.9 - 78.7	19.4 - 85.7		
Sex					0.01 ^b	
Females (%)	182 (57.4)	198 (60.6)	65 (40.9)	445 (55.4)		
Education (Years)					< 0.001 ^c	AMC < PMC = NC
Mean (SD)	11.0 (3.5)	11.3 (3.3)	9.2 (3.9)	10.8 (3.6)		
Range	2.0 - 21.0	2.0 - 21.0	1.0 - 19.0	1.0 - 21.0		
Mutated gene (%)						
C9orf72		121 (37.0)	79 (49.7)	200 (24.9)		
GRN		148 (45.3)	52 (32.7)	200 (24.9)		
MAPT		58 (17.7)	27 (17.0)	85 (10.6)		
TBK1		0 (0.0)	1 (0.6)	1 (0.1)		

^a ANOVA. Differences in age between AMC vs PMC and AMC vs NC. No difference between PMC and NC.

^b Pearson's Chi-squared test.


^c ANOVA. Difference in years of education between AMC vs PMC and AMC vs NC. No difference between PMC and NC.

SUPPLEMENTARY MATERIALS



Supplementary Figure 1. Bar chart illustrating the number of participants at each visit. NC, non-carriers; PMC, presymptomatic mutation carriers; AMC, affected mutation carriers.

SUPPLEMENTARY MATERIALS



Supplementary Figure 2. Trajectories of global cognitive test scores, fitted line from mixed effect model. The model included mutation group (AMC, PMC, NC), visit (1-5), mutation group:visit, years from baseline visit, age, age², education, sex and baseline score as fixed effects and site and individual as random effects. NC, non-carriers; PMC, presymptomatic mutation carriers; AMC, affected mutation carriers. Error bars represent the standard errors of the means.

SUPPLEMENTARY MATERIALS

Supplementary Table 2. Estimates, standard errors and p-values from linear mixed-effects models for the different cognitive domains. Distant PMC, presymptomatic mutation carriers with MORE than 5 years to expected symptom onset; Proximity PMC, presymptomatic mutation carriers with LESS than 5 years to expected onset. Values for the following fixed effects are displayed: mutated gene (including distant vs proximity PMC), visit (1-3) and the interaction between mutated gene and visit. Other fixed effects in model: years from baseline visit, age, age², education, sex and baseline score. Random effects: site and individual. The reference is a female, non-carrier at baseline. Ref = estimates, SE and p-value for each genetic group without interaction with visit. SE=standard error. C9, chromosome 9 open reading frame 72; GRN, progranulin; MAPT, microtubule associated protein tau.

	Global			Language			Executive function			Attention and processing speed			Memory			Social cognition			Visuoconstruction				
	Estimate	SE	p	Estimate	SE	p	Estimate	SE	p	Estimate	SE	p	Estimate	SE	p	Estimate	SE	p	Estimate	SE	p		
Intercept	0.001	0.077	0.992	-0.130	0.148	0.378	-0.179	0.112	0.110	-0.025	0.103	0.807	0.264	0.155	0.090	-0.279	0.223	0.211	0.171	0.146	0.242		
Visit2	0.164	0.026	0.000	0.105	0.051	0.040	0.083	0.038	0.029	0.207	0.036	0.000	0.267	0.057	0.000	0.362	0.146	0.013	0.134	0.055	0.015		
Visit3	0.264	0.045	0.000	0.278	0.087	0.001	0.187	0.066	0.004	0.297	0.061	0.000	0.430	0.098	0.000	0.721	0.264	0.007	0.067	0.094	0.477		
C9	Distant PMC	Ref	-0.024	0.025	0.348	-0.019	0.049	0.693	-0.020	0.036	0.586	-0.038	0.034	0.264	-0.030	0.053	0.576	-0.074	0.069	0.282	-0.034	0.050	0.496
		Visit 2	-0.097	0.040	0.017	-0.092	0.080	0.254	-0.024	0.057	0.676	-0.101	0.055	0.066	-0.168	0.087	0.055	-0.037	0.132	0.779	-0.140	0.084	0.096
		Visit 3	-0.049	0.052	0.353	-0.141	0.104	0.173	0.052	0.074	0.484	0.033	0.071	0.644	0.009	0.112	0.940	-0.132	0.323	0.684	-0.165	0.107	0.123
	Proximity PMC	Ref	-0.025	0.042	0.547	-0.089	0.081	0.271	-0.054	0.060	0.367	-0.008	0.056	0.884	-0.015	0.087	0.864	0.008	0.105	0.937	-0.062	0.083	0.455
		Visit 2	-0.168	0.067	0.013	-0.047	0.134	0.726	-0.021	0.095	0.828	-0.158	0.092	0.086	-0.314	0.146	0.031	0.230	0.182	0.208	-0.450	0.139	0.001
		Visit 3	-0.281	0.089	0.002	-0.410	0.175	0.020	-0.255	0.126	0.043	-0.147	0.120	0.224	-0.387	0.190	0.042	0.348	0.280	0.215	-0.371	0.180	0.040
GRN	Distant PMC	Ref	0.001	0.023	0.978	-0.004	0.045	0.930	-0.001	0.033	0.977	-0.014	0.031	0.644	0.062	0.049	0.206	-0.009	0.066	0.890	0.005	0.046	0.920
		Visit 2	-0.014	0.035	0.681	0.017	0.070	0.804	0.045	0.049	0.359	-0.049	0.047	0.300	-0.057	0.076	0.456	-0.065	0.109	0.551	0.004	0.073	0.961
		Visit 3	-0.058	0.042	0.168	-0.060	0.083	0.473	-0.092	0.059	0.121	-0.009	0.057	0.874	-0.102	0.091	0.258	0.107	0.154	0.489	-0.136	0.086	0.117
	Proximity PMC	Ref	0.019	0.039	0.627	0.012	0.077	0.874	0.020	0.056	0.720	0.052	0.053	0.327	-0.019	0.083	0.817	0.045	0.129	0.728	-0.012	0.078	0.878
		Visit 2	0.007	0.057	0.900	0.200	0.113	0.076	-0.021	0.080	0.794	-0.065	0.077	0.400	-0.121	0.122	0.321	0.340	0.205	0.099	-0.049	0.117	0.676
		Visit 3	-0.148	0.059	0.013	-0.260	0.118	0.028	-0.285	0.084	0.001	-0.223	0.081	0.006	-0.089	0.128	0.486	0.188	0.259	0.470	0.029	0.122	0.813
MAPT	Distant PMC	Ref	0.000	0.036	0.992	-0.008	0.069	0.912	0.018	0.051	0.723	-0.013	0.048	0.787	0.045	0.075	0.548	-0.028	0.102	0.780	-0.013	0.071	0.859
		Visit 2	0.000	0.052	0.992	-0.053	0.103	0.607	-0.059	0.073	0.418	0.120	0.070	0.087	-0.039	0.112	0.726	-0.034	0.154	0.824	-0.067	0.108	0.537
		Visit 3	0.138	0.068	0.042	-0.022	0.135	0.873	0.010	0.096	0.915	0.197	0.092	0.033	0.298	0.146	0.042	0.232	0.253	0.360	0.156	0.139	0.263
	Proximity PMC	Ref	0.000	0.052	0.995	-0.045	0.102	0.660	0.003	0.075	0.973	0.027	0.071	0.703	-0.011	0.110	0.918	0.013	0.150	0.931	-0.019	0.104	0.852
		Visit 2	0.030	0.070	0.672	-0.007	0.141	0.960	0.108	0.099	0.275	0.009	0.096	0.922	0.067	0.154	0.665	0.086	0.217	0.693	0.015	0.150	0.919
		Visit 3	-0.074	0.093	0.428	-0.282	0.185	0.127	-0.142	0.131	0.281	-0.027	0.126	0.830	-0.167	0.201	0.405	0.210	0.458	0.646	0.400	0.191	0.036

SUPPLEMENTARY MATERIALS

Supplementary Table 3. Mixed effects model for global cognitive test scores.

The reference is a female, non-carrier at baseline. The global practice effect in NC was approximately 0.15 SD per visit. We included baseline scores in our statistical models to eliminate the effect of novelty to a task (i.e. stress response at first testing causing interference with performance), and the dilemma of regression to the mean often seen in repeated testing situations. C9, chromosome 9 open reading frame 72; GRN, progranulin; MAPT, microtubule associated protein tau; NC, non-carriers; PMC, presymptomatic mutation carriers; AMC, affected mutation carriers.

Fixed effects	Estimate	Standard Error	p-value
Intercept	0.000	0.076	0.996
Visit 2	0.167	0.026	<0.001
Visit 3	0.270	0.044	<0.001
PMC-C9	-0.025	0.023	0.279
PMC-GRN	0.005	0.021	0.825
PMC-MAPT	-0.002	0.030	0.959
Years from baseline	-0.085	0.013	<0.001
Male	-0.016	0.013	0.229
Age	0.003	0.003	0.416
Age ²	0.000	0.000	0.057
Education (years)	0.003	0.002	0.151
Baseline global score	0.888	0.013	<0.001
Visit 2*PMC-C9	-0.114	0.036	0.002
Visit 3*PMC-C9	-0.104	0.047	0.027
Visit 2*PMC-GRN	-0.008	0.032	0.790
Visit 3*PMC-GRN	-0.086	0.037	0.021
Visit 2*PMC-MAPT	0.011	0.043	0.795
Visit 3*PMC-MAPT	0.064	0.057	0.264
Random effects	Variance		
Individual variance of intercept	0.006		
Site variance of intercept	0.00002		
Residual variance	0.04		

SUPPLEMENTARY MATERIALS

1.5 References

1. Moore KM, Nicholas J, Grossman M, McMillan CT, Irwin DJ, Massimo L, et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. *Lancet Neurol*. 2019;
2. Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Doppert E, Jiskoot L, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. *Lancet Neurol*. 2015 Mar;14(3):253–62.
3. Wechsler D. Manual for the Wechsler abbreviated intelligence scale (WASI). WASI. 1999.
4. Kaplan E, Goodglass H WS. The Boston Naming Test. Philadelphia Lea Febiger. 1983;
5. Corrigan JD, Hinkeldey NS. Relationships between Parts A and B of the Trail Making Test. *J Clin Psychol*. 1987;
6. Lezak MD, Howieson DB, Bigler ED, Tranel D. *Neuropsychological Assessment*. 5th ed. New York: Oxford University Press; 2012. 1200 p.
7. Possin KL, Laluz VR, Alcantar OZ, Miller BL, Kramer JH. Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia. *Neuropsychologia* [Internet]. 2011 Jan [cited 2021 Mar 31];49(1):43–8. Available from: <https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/21029744/>
8. Bozeat S, Lambon Ralph MA, Patterson K, Garrard P, Hodges JR. Non-verbal semantic impairment in semantic dementia. *Neuropsychologia* [Internet]. 2000 Aug 1 [cited 2021 Mar 31];38(9):1207–15. Available from: <https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/10865096/>
9. Stroop JR. Studies of interference in serial verbal reactions. *J Exp Psychol*. 1935;
10. Scarpina F, Tagini S. The stroop color and word test [Internet]. Vol. 8, *Frontiers in Psychology*. Frontiers Research Foundation; 2017 [cited 2021 Mar 31]. p. 557. Available from: </pmc/articles/PMC5388755/>
11. Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. *Neurology* [Internet]. 1988 [cited 2021 Mar 31];38(6):900–3. Available from: <https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/3368071/>
12. Funkiewiez A, Bertoux M, de Souza LC, Lévy R, Dubois B. The SEA (Social cognition and emotional assessment): A clinical neuropsychological tool for early diagnosis of frontal variant of frontotemporal lobar degeneration. *Neuropsychology* [Internet]. 2012 [cited 2021 Mar 31];26(1):81–90. Available from: <https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/21895376/>
13. Song M-K, Lin F-C, Ward SE, Fine JP. Composite variables: when and how. *Nurs Res*. 2013;62(1):45–9.
14. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4 | Bates | *Journal of Statistical Software*. *J Stat Softw*. 2015;

SUPPLEMENTARY MATERIALS

Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study

Linn Öijerstedt^{1,2,3}, Christin Andersson^{4,5}, Vesna Jelic⁶, John C. van Swieten⁷, Lize C. Jiskoot⁷, Harro Seelaar⁷, Barbara Borroni⁸, Raquel Sanchez-Valle⁹, Fermin Moreno^{10,11}, Robert Laforce¹², Matthias Synofzik^{13,14}, Daniela Galimberti^{15,16}, James B. Rowe¹⁷, Mario Masellis¹⁸, Maria Carmela Tartaglia¹⁹, Elizabeth Finger²⁰, Rik Vandenberghe^{21,22,23}, Alexandre de Mendonça²⁴, Fabrizio Tagliavini²⁵, Isabel Santana^{26,27}, Simon Ducharme^{28,29}, Chris R. Butler^{30,31}, Alexander Gerhard^{32,33}, Johannes Levin^{34,35,36}, Adrian Danek³⁷, Markus Otto³⁸, Giovanni B Frisoni³⁹, Roberta Ghidoni⁴⁰, Sandro Sorbi^{41,42}, Jonathan D. Rohrer⁴³, Caroline Graff^{1,2,3}, on behalf of the Genetic Frontotemporal Dementia Initiative (GENFI)

AFFILIATIONS

¹Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden

²Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden

³Swedish FTD Initiative

⁴Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

⁵Department of Medical Psychology, Karolinska University Hospital, Stockholm, Sweden

⁶Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden

⁷Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands

⁸Centre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

⁹Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain

¹⁰Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain

¹¹Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain

¹²Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, QC, Canada

¹³Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany

¹⁴Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany

¹⁵Fondazione IRCCS Ospedale Policlinico, Milan, Italy

¹⁶University of Milan, Centro Dino Ferrari, Milan, Italy

¹⁷Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

¹⁸Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada

¹⁹Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada

²⁰Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario Canada

²¹Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium

²²Neurology Service, University Hospitals Leuven, Belgium

²³Leuven Brain Institute, KU Leuven, Leuven, Belgium

²⁴ Faculty of Medicine, University of Lisbon, Lisbon, Portugal

SUPPLEMENTARY MATERIALS

²⁵Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy

²⁶University Hospital of Coimbra (HUC), Neurology Service, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

²⁷Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

²⁸Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Québec, Canada

²⁹McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Québec, Canada

³⁰Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK

³¹Department of Brain Sciences, Imperial College London, UK

³²Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK

³³Departments of Geriatric Medicine and Nuclear Medicine, University of Duisburg- Essen, Germany

³⁴Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany

³⁵German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

³⁶Munich Cluster of Systems Neurology (SyNergy), Munich, Germany

³⁷Neurologische Klinik, Ludwig-Maximilians-Universität München, Munich, Germany

³⁸Department of Neurology, University of Ulm, Ulm, Germany

³⁹Istituto di Recovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

⁴⁰Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

⁴¹Department of Neurofarba, University of Florence, Italy

⁴²IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy

⁴³Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK

1 Supplemental materials

1.1 Participants

The following clinical information was available for each subject: age at testing, date of testing, sex, mutation status (presymptomatic mutation carrier, PMC; affected mutation carrier, AMC; non-carrier, NC) and years of education. In addition, information on mutated gene (chromosome 9 open reading frame 72, *C9orf72*; progranulin, *GRN*; microtubule associated protein tau, *MAPT* or TANK-binding kinase 1, *TBK1*) was available for mutation carriers, and diagnosis as well as age at onset for affected mutation carriers (AMC).

The mean age at onset for mutation carriers has in a recent publication by Moore *et al.*, 2019(1) been estimated to be 58.2 years for *C9orf72*, 61.3 years for *GRN* and 49.5 years for *MAPT*. Years to expected onset was calculated based on the age of the participant minus the mean age at

SUPPLEMENTARY MATERIALS

onset for the specific mutated gene segregating in the family. For example, a 45 years old *C9orf72* mutation carrier was estimated to be 13.2 years from expected symptom onset ($45 - 58.2 = -13.2$).

1.2 Neuropsychological tests

359 participants were assessed using GENFI 1 protocol (2012-2015) and 444 participants using GENFI 2 protocol (2015-2018)(2). The following tasks were included in both GENFI 1 and GENFI 2 (i.e. all 803 participants performed the tasks): Block design(3), Boston naming test (BNT)(4), Digit symbol(3), Digit span (forward and backward)(3), Trail making test A (TMT A) and B (TMT B)(5) and Verbal fluency test (animals, letters F, A and S)(6). In GENFI 2 (n=444), the following additional tests were administered: Benson figure copy, recall and recognition(7), modified Camel and cactus test (CC)(8), Stroop colour and word test (ink and word naming, interference)(9,10), Free and cued selective reminding test (FCRST)(11), Ekman faces and Faux pas recognition test as part of the mini-SEA(12). All neuropsychological raw scores were converted into z-scores. z-scores were calculated based on mutation negative control data (individual test score minus the mean of non-carriers, divided by the standard deviation of non-carriers) and were corrected for language in language specific tasks (i.e. BNT and Verbal fluency).

1.3 Composite scores

Composite scores were calculated from reflecting different cognitive domains: language, executive function, attention and processing speed, memory, social cognition and visuoconstruction. The composite scores were calculated as the mean of the z-scores of the individual tests included in the composite (13). We treat the composite value as an estimate of a standardised score, meaning that a value of 1 is approximately 1 standard deviation (SD). The composite score of language included BNT, CC and Verbal fluency animals; executive function included TMT B, Verbal fluency letters, Digit span backward and Stroop interference; attention and processing speed included TMT A, Digit symbol, Digit span forward and Stroop ink and word naming; memory included Digit span (forward and backward) and FCRST; social cognition included Ekman faces and Faux pas recognition test (mini-SEA); and visuoconstruction included Block design and Benson figure. If there were missing data from a specific task (if a participant did not complete the whole test battery), the domain composite score was calculated based on the remaining test scores for that domain, i.e. the sum of the z-scores divided by the number of completed tests. As a sensitivity analysis, we excluded the individuals with less

SUPPLEMENTARY MATERIALS

than two thirds of completed tests (n=5) and re-ran the mixed effect model of global cognitive score. The results were the same and did not change the conclusion.

1.4 Statistical analysis

All statistical analyses and visual illustrations were performed using R version 4.0.3. P-values below 0.05 were considered statistically significant and baseline p-values were adjusted for multiple comparisons using Bonferroni corrections (number of comparisons = 63). Assumptions were assessed visually by residual plots (independence and equal variance) and normal probability plots (normality).

When assessing mean differences in numeric variables between NC, PMC and AMC, One-way ANOVA with Bonferroni post hoc tests was used (age, years of education). Chi-square tests were used for assessing sex distribution in NC, PMC and AMC.

Model selection(14) was based upon clinical relevance and Bayesian information criterion (BIC), where lower BIC was preferred. A stepwise backward selection was performed for the fixed effects using R package lmerTest v2.0-36. Mutation group (AMC, PMC or NC) or mutated gene (*C9orf72*, *GRN*, *MAPT*, NC), visit, years from baseline visit, age, age², education, sex and baseline score were included as fixed effects (independent variables) in the final models. In addition, the interaction between gene and visit was included to investigate whether the trajectories for neuropsychological test scores were different over time depending on which gene was mutated. Site and individual were included as random effects to account for within-subject correlations.

SUPPLEMENTARY MATERIALS

Supplementary Table 1. Demographic data. NC, non-carriers; PMC, presymptomatic mutation carriers; AMC, affected mutation carriers; C9orf72, chromosome 9 open reading frame 72; GRN, progranulin; MAPT, microtubule associated protein tau; TBK1, TANK-binding kinase 1; SD, standard deviation.


	Mutation group				Test statistic	
	NC	PMC	AMC	Total	p value	
N	317	327	159	803		
Age (Years)					< 0.001 ^a	AMC > PMC = NC
Mean (SD)	46.2 (14.0)	44.4 (12.0)	62.6 (8.0)	48.7 (14.0)		
Range	19.4 - 85.7	20.1 - 75.5	37.9 - 78.7	19.4 - 85.7		
Sex					0.01 ^b	
Females (%)	182 (57.4)	198 (60.6)	65 (40.9)	445 (55.4)		
Education (Years)					< 0.001 ^c	AMC < PMC = NC
Mean (SD)	11.0 (3.5)	11.3 (3.3)	9.2 (3.9)	10.8 (3.6)		
Range	2.0 - 21.0	2.0 - 21.0	1.0 - 19.0	1.0 - 21.0		
Mutated gene (%)						
C9orf72		121 (37.0)	79 (49.7)	200 (24.9)		
GRN		148 (45.3)	52 (32.7)	200 (24.9)		
MAPT		58 (17.7)	27 (17.0)	85 (10.6)		
TBK1		0 (0.0)	1 (0.6)	1 (0.1)		

^a ANOVA. Differences in age between AMC vs PMC and AMC vs NC. No difference between PMC and NC.

^b Pearson's Chi-squared test.


^c ANOVA. Difference in years of education between AMC vs PMC and AMC vs NC. No difference between PMC and NC.

SUPPLEMENTARY MATERIALS



Supplementary Figure 1. Bar chart illustrating the number of participants at each visit. NC, non-carriers; PMC, presymptomatic mutation carriers; AMC, affected mutation carriers.

SUPPLEMENTARY MATERIALS



Supplementary Figure 2. Trajectories of global cognitive test scores, fitted line from mixed effect model. The model included mutation group (AMC, PMC, NC), visit (1-5), mutation group:visit, years from baseline visit, age, age², education, sex and baseline score as fixed effects and site and individual as random effects. NC, non-carriers; PMC, presymptomatic mutation carriers; AMC, affected mutation carriers. Error bars represent the standard errors of the means.

SUPPLEMENTARY MATERIALS

Supplementary Table 2. Estimates, standard errors and p-values from linear mixed-effects models for the different cognitive domains. Distant PMC, presymptomatic mutation carriers with MORE than 5 years to expected symptom onset; Proximity PMC, presymptomatic mutation carriers with LESS than 5 years to expected onset. Values for the following fixed effects are displayed: mutated gene (including distant vs proximity PMC), visit (1-3) and the interaction between mutated gene and visit. Other fixed effects in model: years from baseline visit, age, age², education, sex and baseline score. Random effects: site and individual. The reference is a female, non-carrier at baseline. Ref = estimates, SE and p-value for each genetic group without interaction with visit. SE=standard error. C9, chromosome 9 open reading frame 72; GRN, progranulin; MAPT, microtubule associated protein tau.

	Global			Language			Executive function			Attention and processing speed			Memory			Social cognition			Visuoconstruction				
	Estimate	SE	p	Estimate	SE	p	Estimate	SE	p	Estimate	SE	p	Estimate	SE	p	Estimate	SE	p	Estimate	SE	p		
Intercept	0.001	0.077	0.992	-0.130	0.148	0.378	-0.179	0.112	0.110	-0.025	0.103	0.807	0.264	0.155	0.090	-0.279	0.223	0.211	0.171	0.146	0.242		
Visit2	0.164	0.026	0.000	0.105	0.051	0.040	0.083	0.038	0.029	0.207	0.036	0.000	0.267	0.057	0.000	0.362	0.146	0.013	0.134	0.055	0.015		
Visit3	0.264	0.045	0.000	0.278	0.087	0.001	0.187	0.066	0.004	0.297	0.061	0.000	0.430	0.098	0.000	0.721	0.264	0.007	0.067	0.094	0.477		
C9	Distant PMC	Ref	-0.024	0.025	0.348	-0.019	0.049	0.693	-0.020	0.036	0.586	-0.038	0.034	0.264	-0.030	0.053	0.576	-0.074	0.069	0.282	-0.034	0.050	0.496
		Visit 2	-0.097	0.040	0.017	-0.092	0.080	0.254	-0.024	0.057	0.676	-0.101	0.055	0.066	-0.168	0.087	0.055	-0.037	0.132	0.779	-0.140	0.084	0.096
		Visit 3	-0.049	0.052	0.353	-0.141	0.104	0.173	0.052	0.074	0.484	0.033	0.071	0.644	0.009	0.112	0.940	-0.132	0.323	0.684	-0.165	0.107	0.123
	Proximity PMC	Ref	-0.025	0.042	0.547	-0.089	0.081	0.271	-0.054	0.060	0.367	-0.008	0.056	0.884	-0.015	0.087	0.864	0.008	0.105	0.937	-0.062	0.083	0.455
		Visit 2	-0.168	0.067	0.013	-0.047	0.134	0.726	-0.021	0.095	0.828	-0.158	0.092	0.086	-0.314	0.146	0.031	0.230	0.182	0.208	-0.450	0.139	0.001
		Visit 3	-0.281	0.089	0.002	-0.410	0.175	0.020	-0.255	0.126	0.043	-0.147	0.120	0.224	-0.387	0.190	0.042	0.348	0.280	0.215	-0.371	0.180	0.040
GRN	Distant PMC	Ref	0.001	0.023	0.978	-0.004	0.045	0.930	-0.001	0.033	0.977	-0.014	0.031	0.644	0.062	0.049	0.206	-0.009	0.066	0.890	0.005	0.046	0.920
		Visit 2	-0.014	0.035	0.681	0.017	0.070	0.804	0.045	0.049	0.359	-0.049	0.047	0.300	-0.057	0.076	0.456	-0.065	0.109	0.551	0.004	0.073	0.961
		Visit 3	-0.058	0.042	0.168	-0.060	0.083	0.473	-0.092	0.059	0.121	-0.009	0.057	0.874	-0.102	0.091	0.258	0.107	0.154	0.489	-0.136	0.086	0.117
	Proximity PMC	Ref	0.019	0.039	0.627	0.012	0.077	0.874	0.020	0.056	0.720	0.052	0.053	0.327	-0.019	0.083	0.817	0.045	0.129	0.728	-0.012	0.078	0.878
		Visit 2	0.007	0.057	0.900	0.200	0.113	0.076	-0.021	0.080	0.794	-0.065	0.077	0.400	-0.121	0.122	0.321	0.340	0.205	0.099	-0.049	0.117	0.676
		Visit 3	-0.148	0.059	0.013	-0.260	0.118	0.028	-0.285	0.084	0.001	-0.223	0.081	0.006	-0.089	0.128	0.486	0.188	0.259	0.470	0.029	0.122	0.813
MAPT	Distant PMC	Ref	0.000	0.036	0.992	-0.008	0.069	0.912	0.018	0.051	0.723	-0.013	0.048	0.787	0.045	0.075	0.548	-0.028	0.102	0.780	-0.013	0.071	0.859
		Visit 2	0.000	0.052	0.992	-0.053	0.103	0.607	-0.059	0.073	0.418	0.120	0.070	0.087	-0.039	0.112	0.726	-0.034	0.154	0.824	-0.067	0.108	0.537
		Visit 3	0.138	0.068	0.042	-0.022	0.135	0.873	0.010	0.096	0.915	0.197	0.092	0.033	0.298	0.146	0.042	0.232	0.253	0.360	0.156	0.139	0.263
	Proximity PMC	Ref	0.000	0.052	0.995	-0.045	0.102	0.660	0.003	0.075	0.973	0.027	0.071	0.703	-0.011	0.110	0.918	0.013	0.150	0.931	-0.019	0.104	0.852
		Visit 2	0.030	0.070	0.672	-0.007	0.141	0.960	0.108	0.099	0.275	0.009	0.096	0.922	0.067	0.154	0.665	0.086	0.217	0.693	0.015	0.150	0.919
		Visit 3	-0.074	0.093	0.428	-0.282	0.185	0.127	-0.142	0.131	0.281	-0.027	0.126	0.830	-0.167	0.201	0.405	0.210	0.458	0.646	0.400	0.191	0.036

SUPPLEMENTARY MATERIALS

Supplementary Table 3. Mixed effects model for global cognitive test scores.

The reference is a female, non-carrier at baseline. The global practice effect in NC was approximately 0.15 SD per visit. We included baseline scores in our statistical models to eliminate the effect of novelty to a task (i.e. stress response at first testing causing interference with performance), and the dilemma of regression to the mean often seen in repeated testing situations. C9, chromosome 9 open reading frame 72; GRN, progranulin; MAPT, microtubule associated protein tau; NC, non-carriers; PMC, presymptomatic mutation carriers; AMC, affected mutation carriers.

Fixed effects	Estimate	Standard Error	p-value
Intercept	0.000	0.076	0.996
Visit 2	0.167	0.026	<0.001
Visit 3	0.270	0.044	<0.001
PMC-C9	-0.025	0.023	0.279
PMC-GRN	0.005	0.021	0.825
PMC-MAPT	-0.002	0.030	0.959
Years from baseline	-0.085	0.013	<0.001
Male	-0.016	0.013	0.229
Age	0.003	0.003	0.416
Age ²	0.000	0.000	0.057
Education (years)	0.003	0.002	0.151
Baseline global score	0.888	0.013	<0.001
Visit 2*PMC-C9	-0.114	0.036	0.002
Visit 3*PMC-C9	-0.104	0.047	0.027
Visit 2*PMC-GRN	-0.008	0.032	0.790
Visit 3*PMC-GRN	-0.086	0.037	0.021
Visit 2*PMC-MAPT	0.011	0.043	0.795
Visit 3*PMC-MAPT	0.064	0.057	0.264
Random effects	Variance		
Individual variance of intercept	0.006		
Site variance of intercept	0.00002		
Residual variance	0.04		

SUPPLEMENTARY MATERIALS

1.5 References

1. Moore KM, Nicholas J, Grossman M, McMillan CT, Irwin DJ, Massimo L, et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. *Lancet Neurol*. 2019;
2. Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Doppert E, Jiskoot L, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. *Lancet Neurol*. 2015 Mar;14(3):253–62.
3. Wechsler D. Manual for the Wechsler abbreviated intelligence scale (WASI). WASI. 1999.
4. Kaplan E, Goodglass H WS. The Boston Naming Test. Philadelphia Lea Febiger. 1983;
5. Corrigan JD, Hinkeldey NS. Relationships between Parts A and B of the Trail Making Test. *J Clin Psychol*. 1987;
6. Lezak MD, Howieson DB, Bigler ED, Tranel D. *Neuropsychological Assessment*. 5th ed. New York: Oxford University Press; 2012. 1200 p.
7. Possin KL, Laluz VR, Alcantar OZ, Miller BL, Kramer JH. Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia. *Neuropsychologia* [Internet]. 2011 Jan [cited 2021 Mar 31];49(1):43–8. Available from: <https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/21029744/>
8. Bozeat S, Lambon Ralph MA, Patterson K, Garrard P, Hodges JR. Non-verbal semantic impairment in semantic dementia. *Neuropsychologia* [Internet]. 2000 Aug 1 [cited 2021 Mar 31];38(9):1207–15. Available from: <https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/10865096/>
9. Stroop JR. Studies of interference in serial verbal reactions. *J Exp Psychol*. 1935;
10. Scarpina F, Tagini S. The stroop color and word test [Internet]. Vol. 8, *Frontiers in Psychology*. Frontiers Research Foundation; 2017 [cited 2021 Mar 31]. p. 557. Available from: </pmc/articles/PMC5388755/>
11. Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. *Neurology* [Internet]. 1988 [cited 2021 Mar 31];38(6):900–3. Available from: <https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/3368071/>
12. Funkiewiez A, Bertoux M, de Souza LC, Lévy R, Dubois B. The SEA (Social cognition and emotional assessment): A clinical neuropsychological tool for early diagnosis of frontal variant of frontotemporal lobar degeneration. *Neuropsychology* [Internet]. 2012 [cited 2021 Mar 31];26(1):81–90. Available from: <https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/21895376/>
13. Song M-K, Lin F-C, Ward SE, Fine JP. Composite variables: when and how. *Nurs Res*. 2013;62(1):45–9.
14. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4 | Bates | *Journal of Statistical Software*. *J Stat Softw*. 2015;